S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
AAPL   263.19 (-1.16%)
FB   197.51 (-0.91%)
MSFT   149.62 (-0.51%)
GOOGL   1,301.86 (-0.82%)
AMZN   1,745.53 (-0.41%)
CGC   17.64 (+15.14%)
NVDA   211.18 (+1.53%)
MU   45.57 (-2.17%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
TSLA   352.22 (-2.03%)
T   37.18 (-2.16%)
AMD   40.98 (-0.75%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
PRI   131.52 (-0.09%)
NFLX   305.16 (+0.85%)
BAC   32.69 (-0.76%)
GILD   64.88 (-0.18%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
AAPL   263.19 (-1.16%)
FB   197.51 (-0.91%)
MSFT   149.62 (-0.51%)
GOOGL   1,301.86 (-0.82%)
AMZN   1,745.53 (-0.41%)
CGC   17.64 (+15.14%)
NVDA   211.18 (+1.53%)
MU   45.57 (-2.17%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
TSLA   352.22 (-2.03%)
T   37.18 (-2.16%)
AMD   40.98 (-0.75%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
PRI   131.52 (-0.09%)
NFLX   305.16 (+0.85%)
BAC   32.69 (-0.76%)
GILD   64.88 (-0.18%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
AAPL   263.19 (-1.16%)
FB   197.51 (-0.91%)
MSFT   149.62 (-0.51%)
GOOGL   1,301.86 (-0.82%)
AMZN   1,745.53 (-0.41%)
CGC   17.64 (+15.14%)
NVDA   211.18 (+1.53%)
MU   45.57 (-2.17%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
TSLA   352.22 (-2.03%)
T   37.18 (-2.16%)
AMD   40.98 (-0.75%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
PRI   131.52 (-0.09%)
NFLX   305.16 (+0.85%)
BAC   32.69 (-0.76%)
GILD   64.88 (-0.18%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
AAPL   263.19 (-1.16%)
FB   197.51 (-0.91%)
MSFT   149.62 (-0.51%)
GOOGL   1,301.86 (-0.82%)
AMZN   1,745.53 (-0.41%)
CGC   17.64 (+15.14%)
NVDA   211.18 (+1.53%)
MU   45.57 (-2.17%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
TSLA   352.22 (-2.03%)
T   37.18 (-2.16%)
AMD   40.98 (-0.75%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
PRI   131.52 (-0.09%)
NFLX   305.16 (+0.85%)
BAC   32.69 (-0.76%)
GILD   64.88 (-0.18%)
DIS   146.93 (-0.98%)
Log in

Savara Stock Price, Forecast & Analysis (NASDAQ:SVRA)

$0.88
-0.02 (-2.22 %)
(As of 11/20/2019 04:00 PM ET)
Today's Range
$0.88
Now: $0.88
$0.97
50-Day Range
$0.71
MA: $0.91
$2.54
52-Week Range
$0.69
Now: $0.88
$11.96
Volume405,200 shs
Average Volume399,013 shs
Market Capitalization$36.26 million
P/E RatioN/A
Dividend YieldN/A
Beta0.1
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SVRA
CUSIPN/A
Phone512-961-1891

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$130,000.00
Book Value$3.08 per share

Profitability

Net Income$-61,520,000.00

Miscellaneous

EmployeesN/A
Market Cap$36.26 million
Next Earnings Date3/11/2020 (Estimated)
OptionableOptionable

Receive SVRA News and Ratings via Email

Sign-up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter.


Savara (NASDAQ:SVRA) Frequently Asked Questions

What is Savara's stock symbol?

Savara trades on the NASDAQ under the ticker symbol "SVRA."

How were Savara's earnings last quarter?

Savara Inc (NASDAQ:SVRA) posted its earnings results on Thursday, November, 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.44) by $0.14. View Savara's Earnings History.

When is Savara's next earnings date?

Savara is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Savara.

What price target have analysts set for SVRA?

6 brokers have issued 1 year price targets for Savara's stock. Their forecasts range from $1.00 to $17.00. On average, they expect Savara's stock price to reach $8.60 in the next year. This suggests a possible upside of 877.3% from the stock's current price. View Analyst Price Targets for Savara.

What is the consensus analysts' recommendation for Savara?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Savara in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Savara.

What are Wall Street analysts saying about Savara stock?

Here are some recent quotes from research analysts about Savara stock:
  • 1. According to Zacks Investment Research, "Savara Inc. is a clinical-stage pharmaceutical company. It focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Savara Inc., formerly known as Mast Therapeutics, Inc., is based in Austin, United States. " (11/8/2019)
  • 2. LADENBURG THALM/SH SH analysts commented, "We believe IMPALA is likely to succeed given GM-CSF’s central role in aPAP, prior trial results and Molgradex’s confirmed low systemic exposure and safety profile. Encouragingly, nearly all eligible patients chose to enroll in the extension trial 26 as of 1Q’19)." (5/10/2019)

Has Savara been receiving favorable news coverage?

Media coverage about SVRA stock has trended neutral this week, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Savara earned a news sentiment score of 0.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Savara.

Are investors shorting Savara?

Savara saw a drop in short interest during the month of October. As of October 31st, there was short interest totalling 791,000 shares, a drop of 18.3% from the September 30th total of 967,700 shares. Based on an average daily trading volume, of 389,700 shares, the short-interest ratio is currently 2.0 days. Currently, 2.4% of the company's shares are sold short. View Savara's Current Options Chain.

Who are some of Savara's key competitors?

What other stocks do shareholders of Savara own?

Who are Savara's key executives?

Savara's management team includes the folowing people:
  • Robert N. Neville, Chairman of the Board, Chief Executive Officer (Age 51)
  • Taneli Jouhikainen, President, Chief Operating Officer (Age 51)
  • David L. Lowrance, Chief Financial Officer (Age 50)
  • Nevan C. Elam, Independent Director (Age 49)
  • Richard J. Hawkins, Independent Director (Age 68)
  • Joseph S. McCracken Ph.D., Independent Director (Age 64)
  • Matthew Pauls J.D., Independent Director (Age 46)
  • Yuri Pikover, Independent Director (Age 56)

How do I buy shares of Savara?

Shares of SVRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Savara's stock price today?

One share of SVRA stock can currently be purchased for approximately $0.88.

How big of a company is Savara?

Savara has a market capitalization of $36.26 million and generates $130,000.00 in revenue each year. The company earns $-61,520,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis. View Additional Information About Savara.

What is Savara's official website?

The official website for Savara is http://www.savarapharma.com/.

How can I contact Savara?

Savara's mailing address is 6836 Bee Cave Road Building III Suite 200, Austin TX, 78746. The company can be reached via phone at 512-961-1891 or via email at [email protected]


MarketBeat Community Rating for Savara (NASDAQ SVRA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  227 (Vote Outperform)
Underperform Votes:  251 (Vote Underperform)
Total Votes:  478
MarketBeat's community ratings are surveys of what our community members think about Savara and other stocks. Vote "Outperform" if you believe SVRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SVRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2019 by MarketBeat.com Staff

Featured Article: Total Return

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel